Follicular Lymphoma
Conference Coverage
CAR T-cell therapy tested in Sweden
NEW YORK—For the first time, according to researchers, chimeric antigen receptor (CAR) T-cell therapy has been tested in a clinical trial in...
News
Obinutuzumab trends better than rituxumab in relapsed indolent lymphoma
Key clinical point: Obinutuzumab was associated with a higher overall response rate as compared with rituximab, but obinutuzumab’s clinical...
News
Lenalidomide + rituximab combo effective in recurrent follicular lymphoma
Key clinical point: Lenalidomide combined with rituximab is more active in recurrent follicular lymphoma, compared with lenalidomide monotherapy....
News
New prognostic model for follicular lymphoma
Photo courtesy of NIH A newly developed prognostic model can identify follicular lymphoma (FL) patients at the highest risk for treatment failure...
News
Early follicular lymphoma progression signals poor outcomes
Key clinical point: Disease progression within 2 years of chemotherapy for follicular lymphoma is associated with poor outcomes. Major finding:...
News
Prenatal test results linked to cancer in mothers
Photo by Nina Matthews Researchers have again found evidence to suggest that tests used to identify chromosomal fetal disorders can detect occult...
News
Early progression predicts overall survival in FL
Photo by Rhoda Baer The goal for many cancer patients is to reach the 5-year mark without progression, but a new study suggests 2 years might be a...
Conference Coverage
Novel mAb targeting CD70 shows activity in TCL
Photo by Linda Bartlett LUGANO—The defucosylated monoclonal antibody (mAb) ARGX-110, which is active against CD70-bearing tumor cells and CD70-...
Conference Coverage
Second pathology review boosts diagnostic accuracy in lymphoma
Key clinical point: A second pathological review of newly-diagnosed lymphoma or suspected lymphoma found discrepancies in 17% of cases. Major...
Conference Coverage
CUDC-907 passes early hurdle in heavily pretreated lymphoma, myeloma
Key clinical point: The dual HDAC and Pi3K inhibitor CUDC-907 was reasonably tolerated and clinically active in a phase I study of heavily...